Avacostar - (PASS)
ConditionANCA-associated Vasculitis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorVifor Fresenius Medical Care Renal Pharma
About this trial
The Avacostar PASS is a non-interventional, multi-national, prospective cohort study that will collect data from 2 cohorts of patients: those treated with avacopan for active severe AAV, and a second cohort treated with a cyclophosphamide or rituximab-based induction regimen without avacopan for active severe AAV. The overall study duration is anticipated to be up to 7 years, including a recruitment period of approximately 3 years.
Eligibility criteria
Qualifiers
Diagnosis of AAV (MPA or GPA), as determined by the Investigator according to their usual practice.
Active, severe AAV at the time of commencing avacopan or non-avacopan SoC induction therapy, in the opinion of the Investigator.
Age ≥18 years of either sex.
Has provided written informed consent.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
500 Participants
are grouped into 2 trial groupsLocations
35Germany
Charité University Medicine Berlin Germany
University Hospital of Cologne Cologne Germany
Municipal Hospital Dresden Dresden Germany
University Hospital Essen Essen Germany
Sponsors and collaborators
Vifor Fresenius Medical Care Renal Pharma
Lead sponsor
Source ClinicalTrials.gov